Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
Michael SchenkerMauricio BurottoMartin RichardetTudor-Eliade CiuleanuAnthony GonçalvesNeeltje SteeghsPatrick SchoffskiPaolo Antonio AsciertoMichele MaioIwona LugowskaLorena LupinacciAlexandra LearyJean-Pierre DelordJulieta GrasselliDavid S P TanJennifer FriedmannJacqueline VukyMarina TschaikaSomasekhar KonduruSai Vikram VemulaRuta SlepetisGeorgia KolliaMisena PaciusQuyen DuongNing HuangParul DoshiJonathan BadenMassimo Di NicolaPublished in: Journal for immunotherapy of cancer (2024)
NCT03668119.